A5040257468- Pharmacogenetics and Drug Metabolism
- Pharmaceutical studies and practices
- Antibiotics Pharmacokinetics and Efficacy
- Pregnancy and Medication Impact
- Statistical Methods in Clinical Trials
- Computational Drug Discovery Methods
- Analytical Chemistry and Chromatography
- Distributed and Parallel Computing Systems
- Scientific Computing and Data Management
- Receptor Mechanisms and Signaling
- Innovative Microfluidic and Catalytic Techniques Innovation
- thermodynamics and calorimetric analyses
- 3D Shape Modeling and Analysis
- Pharmaceutical Economics and Policy
- Human Motion and Animation
- Distributed systems and fault tolerance
- Advanced Drug Delivery Systems
- Drug Transport and Resistance Mechanisms
- Biomedical and Engineering Education
- Electrolyte and hormonal disorders
- Pharmacological Effects and Toxicity Studies
- Monoclonal and Polyclonal Antibodies Research
- 3D Printing in Biomedical Research
- Chemical and Physical Properties in Aqueous Solutions
- Diabetes Management and Research
Bayer (Germany)
2003-2025
University of Florida
2019
Columbus Oncology and Hematology Associates
2019
Leibniz University Hannover
2001
Proteins are an increasingly important class of drugs used as therapeutic well diagnostic agents. A generic physiologically based pharmacokinetic (PBPK) model was developed in order to represent at whole body level the fundamental mechanisms driving distribution and clearance large molecules like proteins. The built extension PK-Sim for small incorporating (i) two-pore formalism drug extravasation from blood plasma interstitial space, (ii) lymph flow, (iii) endosomal (iv) protection by...
This tutorial presents the workflow of adapting an adult physiologically based pharmacokinetic (PBPK) model to pregnant populations using Open Systems Pharmacology (OSP) software suite (www.open-systems-pharmacology.org). is illustrated a previously published PBPK for metronidazole that extrapolated pregnancy by parameterizing and extending structure in terms pregnancy-induced physiological changes. Importantly, this can be applied other scenarios where models need re-parameterized or...
Conducting clinical studies on drug–drug‐gene interactions (DDGIs) and extrapolating the findings into dose recommendations is challenging due to high complexity of these interactions. Here, physiologically‐based pharmacokinetic (PBPK) modeling networks present a new avenue for exploring such complex scenarios, potentially informing guidelines handling patient‐specific DDGIs at bedside. Moreover, they provide an established framework drug–drug interaction (DDI) submissions regulatory...
In 2017, the free and open-source software Open Systems Pharmacology (OSP) was launched. Since then, OSP has evolved from a small community into diverse network of stakeholders committed to advancing solutions for model-informed drug development (MIDD). this context, first Community Conference hosted by Novartis in Basel, Switzerland, on October 7-8, 2024, which gathered over 100 attendees more than 40 institutions. This perspective synthesizes key insights conference.
Natural scientists such as physicists pioneered the sharing of computing resources, which resulted in Grid. The inter domain transfer process this technology has been an intuitive process. Some difficulties facing life science community can be understood using Bozeman's “Effectiveness Model Technology Transfer”. and classical approaches deal with technologies that have achieved certain stability. Grid Cloud solutions are still flux. We illustrate how creates new for not...